146 results on '"Xiao, Mingzhe"'
Search Results
2. SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
3. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report
4. LIF Promotes Sec15b‐Mediated STAT3 Exosome Secretion to Maintain Stem Cell Pluripotency in Mouse Embryonic Development.
5. Eco-Friendly Shield Muck-Incorporated Grouting Materials: Mix Optimization and Property Evaluation for Silty Clay Tunnel Construction.
6. Differences of inflammatory and non-inflammatory indicators in Coronavirus disease-19 (COVID-19) with different severity
7. Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation
8. EPS15–NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma
9. Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA
10. Reply to: Binding site for MDL-801 on SIRT6
11. Identification of a cellularly active SIRT6 allosteric activator
12. A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity
13. Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment
14. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
15. SIRT4-Catalyzed Deacetylation of Axin1 Modulates the Wnt/β-Catenin Signaling Pathway
16. Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report
17. Long non‐coding RNA TDRG1 aggravates colorectal cancer stemness by binding with miR‐873‐5p to upregulate PRKAR2
18. Genomic signatures in young and old Chinese patients with bone and soft tissue tumors.
19. PAPPA2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC and SKCM.
20. ANK2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
21. Slit mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
22. XIRP2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
23. Comprehensive molecular characterization of Chinese patients with biliary tract cancers.
24. NPAP1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
25. The predictive values of POTEE mutations for response to immune checkpoint inhibitors in lung adenocarcinoma.
26. Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.
27. Genomic characterization of primary cervical cancer and lung metastasis.
28. Immune-suppressive microenvironment was revealed from NSCLC patients with hyperprogressive disease (HPD) from immunotherapy.
29. DYNC2H1 Mutation as an indicator stratified patients benefit from Immune Checkpoint Inhibitors in NSCLC.
30. WDR49 mutation as a novel predictive biomarker in patients with non–small cell lung cancer with immune checkpoint inhibitors.
31. Clinical significance of next generation sequencing (NGS) in Chinese patients with relapsed/refractory Wilm’s tumor.
32. ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.
33. NOTCH1 Mutation Impairs the Adaptive Immune Response, Leading to Decreased Relapse-Free Survival In Patients with Resected T1-2N0 Laryngeal Cancer
34. A novel DPP10 (intergenic)-NTRK3 fusion in a patient with facial malignant melanoma and potentially benefit from NTRK inhibitors
35. Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report
36. Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib
37. Chr1 95026203-ALK, a novel intergenic fusion identified in a patient with lung adenocarcinoma with nodular ground-glass opacity
38. Long non‐coding RNATDRG1 aggravates colorectal cancer stemness by binding with miR‐873‐5p to upregulate PRKAR2.
39. Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
40. Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations
41. Characterization of NTRK gene fusion events in solid tumors among Chinese patients.
42. YAP1 mutation as a novel predictor of response to anti-PD-1/PD-L1 treatment in pan-cancers.
43. Retrospective analysis of efficacy of immune checkpoint inhibitors in BRCA-mutant non-small cell lung cancer.
44. FAT4 mutation serve as a novel predictor of response to anti-PD-1/PD-L1 treatment in melanoma.
45. Correlation of NFE2L2 mutation with higher tumor mutation burden (TMB), microsatellite instability (MSI) and PD-L1 expression in 3,716 cases of Chinese pan-cancer.
46. DNA and RNA sequencing analysis revealed alterations of ANK3, PKHD1 and olfactory transduction as potential biomarker of three-year survival in gastric cancer.
47. Successful treatment of pulmonary lymphangitic carcinomatosis by anlotinib in 14 Chinese patients with advanced non-small cell lung cancer.
48. Immunoregulation related gene of CSMD2 and RNA activity as potential predicter of 2-year survival in pancreatic cancer: A DNA and RNA sequencing analysis.
49. Landscape of hyper-progression related gene alterations among Chinese population and their impact on patients’ survival after immunotherapy.
50. PREX2 mutation serves as a novel predictor of response to anti-PD-1/PD-L1 treatment in melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.